May & Baker Nigeria Plc (MAYBAK.ng) Q12022 Interim Report

By Published On: April 28, 2022TYPE: Interim ReportsYear: 2022Period: Q1Country: NigeriaSector: Pharmaceuticals

May & Baker Nigeria Plc (MAYBAK.ng) listed on the Nigerian Stock Exchange under the Pharmaceuticals sector has released it’s 2022 interim results for the first quarter.

For more information about May & Baker Nigeria Plc reports, abridged reports, interim earnings results and earnings presentations visit the May & Baker Nigeria Plc company page on AfricanFinancials.

Indicative Share Trading Liquidity

The total indicative share trading liquidity for May & Baker Nigeria Plc (MAYBAK.ng) in the past 12 months, as of 3rd April 2022, is US$541.88K (NGN413.9M). An average of US$45.16K (NGN34.49M) per month.

May & Baker Nigeria Plc Interim Results for the First Quarter Document

Company Profile

May & Baker Nigeria Plc manufactures and markets a range of pharmaceuticals, vaccines, medical diagnostics, foods and consumer healthcare products in Nigeria. Pharmaceutical products include anti-diabetics, anti-infectives, anti-malaria, analgesics, cough & cold treatments, multivitamins and anxiolytics. May & Bake Nigeria Plc produce a range of Mimee noodles and Lily still water. The company’s head office is in Lagos, Nigeria. May & Baker Nigeria Plc is listed on the Nigerian Stock Exchange

May & Baker Nigeria Plc (MAYBAK.ng)

Share price: 3.97 NGN (0.00 | 0.00% – 27/06/22)

Sign up for Email Alerts

Recent Documents & News